A Phase 3 interventional study of MET097 and Placebo in Obesity and Overweight, sponsored by Pfizer. Active, not recruiting at 161 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing berobenatide in Obesity — 11 open to participants now, 15 under way, 12 of them phase 3. berobenatide · Obesity.
Among the 21 studies testing berobenatide in Obesity, this one has the largest enrollment, is one of 4 that started in 2025, is one of 12 in phase 3, reaches primary completion later than 3 of the 14 other live ones, and was the 6th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →11 of the 21 studies testing berobenatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in Japan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 12
First in 2024; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,578 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 258 across the 21 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 21 have an industry lead sponsor. The 2 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
64 studies in Obesity by Pfizer: 13 open now, 19 under way, 12 of them phase 3. Of 43 finished, 11 (26%) have results posted.
Among the 64 studies in Obesity by Pfizer, this one has the largest enrollment of the 62 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 in phase 3, reaches primary completion later than 6 of the 18 other live ones, and was the 45th registered.
Pfizer’s Obesity studies by the year they started, since 2004.
5 of the studies testing berobenatide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311850Phase 3PfizerEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | 2027-09-21 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07508241PfizerA Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity | 2027-01-27 |
| NCT07845513PfizerA Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity | 2027-02-21 |
| NCT07876531PfizerA Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity | 2027-04-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 21 studies testing berobenatide in Obesity, from their registry updates:
Among Pfizer’s 64 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MET097 administered subcutaneously
Drug: MET097
Participants will receive MET097 administered subcutaneously
Drug: MET097
Participants will receive MET097 administered subcutaneously
Drug: MET097
Once-weekly placebo administered via subcutaneous injection
Drug: Placebo
Once-weekly MET097 administered via subcutaneous injection
Also known as: PF-08653944
Once-weekly placebo administered via subcutaneous injection
Percent change from baseline in body weight
Time frame: Baseline (Day 0) to Week 64
Percentage of Participants who achieve ≥5% of reduction from baseline body weight
Time frame: Baseline (Day 0) to Week 64
Percentage of Participants who achieve ≥10% of reduction from baseline body weight
Time frame: Baseline (Day 0) to Week 64
Percentage of Participants who achieve ≥15% of reduction from baseline body weight
Time frame: Baseline (Day 0) to Week 64
Percentage of Participants who achieve ≥20% of reduction from baseline body weight
Time frame: Baseline (Day 0) to Week 64
Change from baseline in Fasting triglycerides
Time frame: Baseline (Day 0) to Week 64
Change from baseline in non-high-density lipoprotein-cholesterol (non-HDL-C) (mg/dL)
Time frame: Baseline (Day 0) to Week 64
Change from baseline in systolic blood pressure
Time frame: Baseline (Day 0) to Week 64
Change from baseline in the Short Form 36 health survey (SF-36) physical function domain score
Time frame: Baseline (Day 0) to Week 64
Change from baseline in body weight
Time frame: Baseline (Day 0) to Week 84
Percentage of Participants who achieve ≥5% of reduction from baseline body weight
Time frame: Baseline (Day 0) to Week 84
Percentage of Participants who achieve ≥10% of reduction from baseline body weight
Time frame: Baseline (Day 0) to Week 84
Percentage of Participants who achieve ≥15% of reduction from baseline body weight
Time frame: Baseline (Day 0) to Week 84
Percentage of Participants who achieve ≥20% of reduction from baseline body weight
Time frame: Baseline (Day 0) to Week 84
Change from baseline in Fasting triglycerides
Time frame: Baseline (Day 0) to Week 84
Change from baseline in non-high-density lipoprotein-cholesterol (non-HDL-C)
Time frame: Baseline (Day 0) to Week 84
Change from baseline in systolic blood pressure (mmHg)
Time frame: Baseline (Day 0) to Week 84
Change from baseline in the Short Form 36 health survey (SF-36) physical function domain score
Time frame: Baseline (Day 0) to Week 84
Change from baseline in waist circumference (cm)
Time frame: Baseline (Day 0) to Week 64 and Week 84
Change from baseline in glycated hemoglobin (HbA1c)
Time frame: Baseline (Day 0) to Week 64 and Week 84
Change from baseline in fasting plasma glucose (FPG)
Time frame: Baseline (Day 0) to Week 64 and Week 84
Change from baseline in fasting insulin
Time frame: Baseline (Day 0) to Week 64 and Week 84
Change from baseline in total cholesterol
Time frame: Baseline (Day 0) to Week 64 and Week 84
Change from baseline in low-density lipoprotein-cholesterol (LDL-C)
Time frame: Baseline (Day 0) to Week 64 and Week 84
Change from baseline in very low-density lipoprotein-cholesterol (VLDL-C)
Time frame: Baseline (Day 0) to Week 64 and Week 84
Change from baseline in high-density lipoprotein-cholesterol (HDL-C)
Time frame: Baseline (Day 0) to Week 64 and Week 84
Change from baseline in DBP
Time frame: Baseline (Day 0) to Week 64 and Week 84
Percent change from baseline in high-sensitivity C-reactive protein (hs-CRP)
Time frame: Baseline (Day 0) to Week 64 and Week 84
Change from baseline in EuroQoL 5-Dimension 5-Level (EQ5D-5L)
Time frame: Baseline (Day 0) to Week 64 and Week 84
Change from baseline in Control of Eating Questionnaire (CoEQ)
Time frame: Baseline (Day 0) to Week 64 and Week 84
Change from baseline in Food Noise Questionnaire (FNQ)
Time frame: Baseline (Day 0) to Week 64 and Week 84
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: Week 84
Number of Participants with Serious adverse events (SAEs)
Time frame: Week 84
Number of Participants with Adverse Events of Clinical Interest (AECIs
Time frame: Week 84
Number of Participants With Clinical Laboratory Abnormalities
Time frame: Week 84
Number of participants with anti-drug antibodies (ADAs)
Time frame: Week 84
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of PF-08653944
Time frame: Week 84
Change from baseline in body weight
Time frame: Baseline (Day 0) to Week 64
Percent change from baseline in body weight
Time frame: Baseline (Day 0) to Week 84
Showing the first 100 of 161 sites across 10 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 21 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Berobenatide